Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1888
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis ; day:26 ; month:10 ; year:2021 ; pages:1-11
American journal of clinical dermatology ; (26.10.2021), 1-11
- Creator
-
Silverberg, Jonathan I.
Simpson, Eric L.
Armstrong, April W.
Bruin-Weller, Marjolein S. de
Irvine, Alan D.
Reich, Kristian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40257-021-00639-y
- URN
-
urn:nbn:de:101:1-2022011519331508006578
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Silverberg, Jonathan I.
- Simpson, Eric L.
- Armstrong, April W.
- Bruin-Weller, Marjolein S. de
- Irvine, Alan D.
- Reich, Kristian
- SpringerLink (Online service)
Other Objects (12)
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study